U.S. markets open in 3 hours 57 minutes

  • S&P Futures

    3,949.00
    +18.00 (+0.46%)
     

  • Dow Futures

    31,585.00
    +188.00 (+0.60%)
     

  • Nasdaq Futures

    13,859.75
    +55.00 (+0.40%)
     

  • Russell 2000 Futures

    2,307.80
    +21.40 (+0.94%)
     

  • Crude Oil

    59.77
    +0.30 (+0.50%)
     

  • Gold

    1,823.30
    +0.10 (+0.01%)
     

  • Silver

    27.82
    +0.49 (+1.80%)
     

  • EUR/USD

    1.2164
    +0.0025 (+0.21%)
     

  • 10-Yr Bond

    1.2000
    0.0000 (0.00%)
     

  • Vix

    21.12
    -0.13 (-0.61%)
     

  • GBP/USD

    1.3924
    +0.0022 (+0.16%)
     

  • USD/JPY

    105.2430
    -0.0880 (-0.08%)
     

  • BTC-USD

    49,112.67
    +1,526.71 (+3.21%)
     

  • CMC Crypto 200

    999.63
    +42.92 (+4.49%)
     

  • FTSE 100

    6,770.23
    +14.12 (+0.21%)
     

  • Nikkei 225

    30,467.75
    +383.60 (+1.28%)
     

Hospital Acquired Infections Therapeutic Market Size Worth $12.5 Billion By 2027: Grand View Research, Inc.

·4 min read

SAN FRANCISCO, Feb. 16, 2021 /PRNewswire/ -- The global hospital acquired infections therapeutic market size is expected to reach USD 12.5 billion by 2027, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 2.4% from 2020 to 2027. The high prevalence of HAIs, rise in approval and launch of new drugs, and growing hospitalization due to the rise in prevalence of chronic diseases are driving the market.

Grand View Research Logo
Grand View Research Logo

Key suggestions from the report:

  • Antibacterial drugs dominated the drug class segment in 2019, owing to the high adoption of antibiotics as the first line of treatment for hospital-acquired infections (HAIs)

  • The surgical site infections (SSIs) segment held the largest market share in 2019 due to the rising number of surgical procedures and subsequent rising cases of SSIs

  • The urinary tract infections (UTIs) segment is anticipated to show the fastest growth rate during the forecast period owing to the growing number of UTI cases and rising awareness among people about the disease condition in less-developed countries

  • The introduction of novel drugs by key players, for instance, Merck to treat ventilator-associated pneumonia has led to a high growth of the market

  • The high prevalence of HAIs in the European countries is the major factor significantly driving the demand for its medications in this region

  • Growing awareness levels about various risk factors associated with HAIs in ICU and other emergency care settings is expected to propel market growth in the Asia Pacific region

Read 120 page research report with ToC on "Hospital Acquired Infections Therapeutic Market Size, Share & Trends Analysis Report By Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs), By Infection Type, By Region, And Segment Forecasts, 2020 - 2027'' at: https://www.grandviewresearch.com/industry-analysis/hospital-acquired-infections-therapeutic-market

According to the data published by the New York State Department of Health in November 2019, around 160 hospitals in New York reported total cases of around 1,139 colon SSIs out of 19,732 procedures in 2018, a rate of 5.8 infections per 100 procedures. The same source also states that in 2018, around 15,310 cases of Clostridioides difficile infections (CDI) were reported in acute care hospitals located in New York. Such, high prevalence of hospital-acquired infections is anticipated to significantly raise the demand for its treatment therapies and support the HAIs therapeutics market growth over the forecast period.

Furthermore, key players in the market are involved in extensive R&D initiatives for the development and indication expansion of its already approved drugs for HAI treatment. For instance, in February 2018, the FDA approved Allergan plc's supplemental New Drug Application (sNDA) and expanded the approval of Avycaz (ceftazidime and avibactam) to include the treatment of HABP/VABP and hospital-acquired bacterial pneumonia.

Grand View Research has segmented the global hospital acquired infections therapeutic market report on the basis of drug class, infection type, and region:

  • HAIs Therapeutics Drug Class Outlook (Revenue, USD Million, 2016 - 2027)

  • HAIs Therapeutics Infection Type Outlook (Revenue, USD Million, 2016 - 2027)

  • HAIs Therapeutics Regional Outlook (Revenue, USD Million, 2016 - 2027)

List of Key Players of Hospital Acquired Infections Therapeutic Market

  • Merck & Co., Inc.

  • Pfizer Inc.

  • Bayer AG

  • GlaxoSmithKline Plc.

  • Daiichi Sankyo Company, Limited

  • AbbVie Inc.

  • Abbott Laboratories

  • F. Hoffmann-La Roche Ltd

  • Allergan Plc.

Find more research reports on Pharmaceuticals Industry, by Grand View Research:

Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com
Follow Us: LinkedIn | Twitter

Cision
Cision

View original content:http://www.prnewswire.com/news-releases/hospital-acquired-infections-therapeutic-market-size-worth-12-5-billion-by-2027-grand-view-research-inc-301228678.html

SOURCE Grand View Research, Inc.

Latest Stories

  • The Single Biggest Threat To The Electric Vehicle Boom

    Toyota’s boss is predicting this could lead to the collapse of the auto industry. But one company may hold the solution...

  • GameStop Investors Who Bet Big—and Lost Big

    GameStop’s volatile ride is hitting the portfolios of individual investors who purchased the stock in a social-media-fueled frenzy.

  • Dow Jones Futures: Be Ready For A Stock Market Rally Pullback Or Melt Up; Analyzing Apple, Amazon, Palantir

    The stock market could pull back or melt up, are you ready? Apple and Amazon are setting up, while Palantir earnings are on tap.

  • Morgan Stanley Storms Into the EV Space; Offers 2 Stocks to Buy

    We are indeed living in interesting times – and in many ways, that’s a good thing. Take the automotive industry, for example. Technology is changing a rapid pace, and when it settles, it will dramatically change the way we drive. In 2030, our concept of ‘car’ will likely be unrecognizable to drivers from 1980. The biggest changes are coming from power systems and artificial intelligence. AI will bring autonomous tech to our cars, making self-driving vehicles a reality. But the power systems changes will hit us first. In fact, electric-drive vehicles are already on our roads, and electric vehicle (EV) companies are proliferating rapidly. For the moment, there are several roads to potential success in the EV market. Companies are working to position themselves as leaders in battery tech, or electric power trains, or to maximize their range and performance per charge. It’s a fact-paced industry environment, offering both opportunity and excitement for investors. Smart investors will look for companies capable of meeting scaling demands, once they have settled on marketable models. Investment firm Morgan Stanley has been watching the EV industry, seeking out innovative new design and production companies that are positioning themselves for gains as the market matures. The firm’s automotive analyst, Adam Jonas, has selected two stocks that investors should seriously consider buying into, saying “As we survey the EV/battery startup landscape, we are prioritizing highly differentiated technology and/or business models with a path to scale at a reasonable level of risk.” Opening up the TipRanks database, we’ve pulled up the details on both of Jonas’ picks to see whether they could be a good fit for your portfolio. Fisker (FSR) First up, Fisker, is based in Southern California, the epicenter of so much of our ground-breaking tech industries. Fisker’s focus is on solid-state battery tech, a growing alternative to the lithium-ion batteries that most EVs depend on. While more expensive that the older lithium-based systems, solid state batteries are safer and offer higher energy densities. Fisker has been busy patenting its moves into solid-state batteries, a sound strategy to lock in its advances in this field. For EVs, solid-state batteries offer faster charging times, longer range per charge, and potentially lower battery weight – all important factors in vehicle performance. Every car company needs a flagship model, and Fisker has the Ocean – an EV SUV with a mid-range price ($37,499) and a long-range power system (up to 300 miles). The vehicle features stylish design and room mounted solar panels to supplement the charging system, and is scheduled to enter serial production for the markets in 2022. The stylish design reflects the sensibilities of the company’s founder, Henrik Fisker, known for his work on the BMW Z8 and the Aston Martin DB9. Fisker entered the public markets through a SPAC merger agreement last fall. Since completing the SPAC transaction on October 29, shares in FSR are up 112%. Morgan Stanley’s Jonas is impressed by this company, describing the ‘value proposition of Fisker’ as “…design, time to market, clean sheet user experience and management expertise,” and saying that the 4Q22 launch schedule for the Ocean is likely to be met. “Fisker is specifically targeting the personal owned/passenger car business as opposed to commercial oriented end markets, where emotive design and user experience matter more. Additionally, the company wants to create an all-digital experience from the website to the app to the HMI in the car and continued customer engagement through its flexible lease product,” Jonas added. In line with his upbeat outlook on the company (and the car), Jonas rates Fisker an Overweight (i.e. Buy), and sets a $27 price target suggesting an upside of 42% for the coming year. (To watch Jonas’ track record, click here) Turning to the TipRanks data, we’ve found that Wall Street’s analysts hold a range of views on Fisker. The stock has a Moderate Buy analyst consensus rating, based on 7 reviews, including 4 Buys, 2 Holds, and 1 Sell. Shares are currently priced at $18.99, and the $21.20 average price target implies a one-year upside of ~12%. (See FSR stock analysis on TipRanks) QuantumScape (QS) Where Fisker is working on solid-state batteries in the context of vehicle production, QuantumScape is setting itself up as a leader in EV battery technology and a potential supplier of the next generation of battery and power systems for the EV market. QuantumScape designs and builds solid-state lithium-metal batteries, the highest energy density battery system currently available. The key advantages of the technology are in safety, lifespan, and charging times. Solid-state batteries are non-flammable; they last longer than lithium-ion batteries, with less capacity loss at the anode interface; and their composition allows faster charging, of 15 minutes or less to reach 80% capacity. QuantumScape is betting that these advantages will outweigh the technology’s current higher cost, and create a new standard in EV power systems. The company’s strongest tie to the EV production field is its connection with Volkswagen. The German auto giant put $100 million into QuantumScape in 2018, and an additional $200 million in 2020. The two companies are using their partnership to prepare for mass-scale development and production of solid-state batteries. Like Fisker, QuantumScape went public through a SPAC agreement late last year. The agreement, which closed on November 27, put the QS ticker in the public markets – where it promptly surged above $130 per share. While the stock has since slipped, it remains up 47% from its NYSE opening. For Morgan Stanley’s Jonas, involvement in QS stock comes with high risk, but also high potential reward. In fact, the analyst calls it, "The Biotech of Battery Development." "We believe their solid state technology addresses a very big impediment in battery science (energy density) that, if successful, can create extremely high value to a wide range of customers in the auto industry and beyond. The risks of moving from a single layer cell to a production car are high, but we think these are balanced by the commercial potential and the role of Volkswagen to help underwrite the early manufacturing ramp," Jonas explained. Noting that QS is a stock for the long haul, Jonas rates the shares an Overweight (i.e. Buy), and his $70 price target indicates confidence in an upside of 28% for one-year time horizon. Granted, not everyone is as enthusiastic about QS as Morgan Stanly. QS's Hold consensus rating is based on an even split between Buy, Hold, and Sell reviews. The shares are priced at $54.64 and their recent appreciation has pushed them well above the $46.67 average price target. (See QS stock analysis on TipRanks) To find good ideas for EV stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • 21 stocks Goldman Sachs thinks you should consider buying now

    Goldman Sachs is bullish on the economic recovery, and has offered up a list of stocks it thinks you should consider buying.

  • Palantir’s 340% Rally Faces Key Tests in Earnings, Lockup’s End

    (Bloomberg) -- Palantir Technologies Inc.’s blistering rally will face two key events this week with an earnings report on Tuesday morning, followed by the expiration of a lockup three days later that could unleash a wave of selling from insiders tempted to cash in their shares.The data-mining company’s stock has more than quadrupled in the seven months since its direct listing amid a string of high-profile sales deals and interest from retail traders. The gains have raised concerns on Wall Street that Palantir could be in for a turbulent week if it’s unable to meet expectations that have risen along with the share price.“We remain positive on the long-term opportunity ahead,” said Brent Thill, an analyst with Jefferies who has a buy rating on the stock. “However, we acknowledge the need for near-term caution.”Palantir is expected to report revenue of $300.8 million, according to data compiled by Bloomberg. That would result in annual revenue of $1.07 billion, up 44% from 2019. While Palantir is likely to beat estimates, it’s annual sales forecast could fall short of expectations, according to Morgan Stanley.The company’s market valuation at 39 times 2021 sales estimates implies revenue growth well in excess of 40%, which could be difficult to achieve, said analyst Keith Weiss, who has the equivalent of a sell rating.“Add on an impending lock-up release of ~80% of total shares three trading days post 4Q20 results and the premium valuation, we see a decidedly negative risk-reward,” he wrote in a research note.There are signs that investors are heeding these warnings. Palantir shares have declined for two consecutive weeks and are down 18% from a record high late last month. Despite the pullback, the stock is still trading more than 60% above the average price target on Wall Street.Details on Palantir’s larger sales deals will be a big focus for investors on Tuesday, according to Jefferies’s Thill. Among deals reported in the past three months are a $44 million contract with the U.S. Food and Drug Administration and a partnership with International Business Machines Corp. to offer its software through the tech giant.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • Exclusive: Battery recycler Li-Cycle nears SPAC deal to go public - sources

    Li-Cycle Corp, a recycler of lithium-ion batteries, is nearing a deal to go public through a merger with blank-check acquisition company Peridot Acquisition Corp at a valuation of about $1.7 billion, according to people familiar with the matter. The deal could be announced as early as Tuesday, the sources said, requesting anonymity ahead of an official announcement. It represents a bet on the growing market for recycling used batteries, as well on the rising demand for lithium-ion power sources for new technologies such as electric vehicles.

  • Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week

    Welcome to the Cannabis Countdown, the Legal Marijuana Industry’s Number One Curated Weekly News Recap. In This Week’s Edition, We Recap and Countdown the Top 10 Cannabis and Psychedelic Stock News Stories for the Week of February 8th – 14th, 2021. Without further ado, let’s get started. * Yahoo Finance readers, please click here to view the full article. 10. Pot Stocks Cap Off Week of Euphoric Gains, Top 30 Performers of the Week and YTD 2021 Investor euphoria in the cannabis sector reached a fever pitch this week as pot stocks went parabolic, producing gains of up to 238.89% in a span of just 3 days It’s official; the American Cannabis Boom 2.0 is in full flight as major market catalysts in the form of U.S. federal Marijuana reforms appear imminent. With federal legalization in the U.S. inching closer to becoming a reality, money is pouring into the Cannabis market like never before, and as a result, Pot Stocks have already seen astonishing YTD 2021 gains of up to 359.37%, 694.78% and 945.71%. READ FULL TOP POT STOCKS ARTICLE HERE 9. Psychedelics Advocate, Investor Zappy Says 2021 is ‘The Year to Invest in Plant Medicine’ Get Into Psychedelics Now, That’s According to Michael “Zappy” Zapolin, a Former Bear Stearns VP Turned Psychedelics Advocate and Filmmaker Zappy’s call to invest comes as Psychedelics make a continued push towards credibility on the medical, legal and business stages. The market — projected to be valued at over $6.8 billion in North America by 2027 — is currently led by MindMed (OTCQB: MMEDF), Cybin Inc. (OTC: CLXPF), Field Trip Health (OTC: FTRPF). Last month, the first Psychedelics ETF — Horizons Psychedelic Stock Index ETF (NEO: PSYK) — began trading on the Canadian NEO Exchange. This is fertile ground for Zappy, who has a track record of getting in on the ground floor. READ FULL PSYCHEDELICS INVESTING ARTICLE 8. Portnoy Flips Sundial Growers For K Profit: ‘That’s How You Do It Boys’ On Thursday Morning, Portnoy Tweeted That He Was “Back in $SNDL Cause I Love the Rush.” and About 25 Minutes Later, Portnoy Indicated He Had Flipped the Volatile Stock for a Big Gain Sundial Growers (NASDAQ: SNDL) shares traded down 14% on massive volume in an extremely volatile trading session on Thursday after the company became one of the latest stocks targeted by communities of online retail stock traders, led by the Reddit WallStreetBets community. Barstool Sports founder Dave Portnoy took a major bath on his first round of WallStreetBets meme stock buys, but Portnoy said he made a quick $50,000 getting in and out of Sundial on Thursday. READ FULL PORTNOY SUNDIAL ARTICLE 7. COMPASS Pathways Expands its Discovery Center Through New Collaborations With World-Leading Scientists Adam Halberstadt and John McCorvy Join Jason Wallach to Develop New Psychedelic Compounds at the Virtual Discovery Center Compass Pathways (NASDAQ: CMPS) announced that it has expanded its Discovery Center, through collaborations with world-leading laboratories at UC San Diego, School of Medicine, and Medical College of Wisconsin (MCW). Adam Halberstadt PhD, Associate Professor, Psychiatry, UC San Diego, and John D McCorvy PhD, Assistant Professor, Department of Cell Biology, Neurobiology and Anatomy, MCW, and their teams, will join Jason Wallach PhD, Assistant Professor of Pharmaceutical Sciences, University of the Sciences (Philadelphia), at the Discovery Center, a group of researchers working together, virtually. READ FULL COMPASS PATHWAYS ARTICLE 6. Red White & Bloom Arranges Approximately US$13.5 Million to Finance its Closing Costs for Illinois Acquisition RWB Received an $8 Million Warrant Exercise From an Institutional Investor and Signed an Irrevocable $7 Million Non-Convertible Debenture Unit Financing Commitment Red White & Bloom (OTCQX: RWBYF) announced that it has arranged the required cash for the closing of its previously announced acquisition of an Illinois Adult Use and Medical Cannabis Cultivation Center License and Associated Assets. Upon closing, and subject to regulatory approval, the Company intends to introduce both its Platinum Vape and High Times branded products into the Illinois market. “Surpassing USD $1 billion of adult-use sales in only its first year, Illinois has quickly developed into one of the most robust revenue markets in the United States. With the financing now secured, we are thrilled to be one step closer to bringing Red White & Bloom’s nationally-recognized brands to this market. The renewed optimism around the State permitting an additional 75 retail locations further highlights the enormous opportunity Illinois offers.” READ FULL RED WHITE & BLOOM ARTICLE 5. Creso Pharma Makes Move to Accelerate Sales Growth and Increase Profit Margins In Response to a Growing Trend of Direct Inbound cannaQIX Sales Enquiries, Creso is Officially Taking Over the Reins From its Swiss Commercial Partner Doetsch Grether Creso Pharma (OTC: COPHF) announced that the company has brought the sales and marketing of its cannaQIX product inhouse. By doing so, Creso Pharma will be able to improve its profit margin on the product substantially. The move will also set the stage for Creso to extend existing product lines and launch new products such as cannaDOL in Switzerland. READ FULL CRESO PHARMA ARTICLE 4. Incannex Shares Jump as Cannabis/Psychedelic Pharma Company Explores Dual Listing on NYSE or NASDAQ The Timing Seems Right, as Both the Cannabis and Psychedelic Sectors Certainly Seem in Vogue at the Moment, Following Efforts at Regulatory Reform and Increasing Acceptance Around the Globe Incannex Healthcare (FRA: IQI) has announced it will explore a dual listing in the United States, a pioneering step that would give the pharmaceutical development company access to the world’s largest pool of capital as it works to develop cannabis and psychedelic-based therapies. Incannex shares nearly reached a seven-year high after the Melbourne-based company said it had signed EAS Advisors on as consultants to introduce it to U.S. banks and institutions. The aim is to obtain a dual listing on the New York Stock Exchange (NYSE) or the NASDAQ, while also retaining an ASX listing. READ FULL INCANNEX ARTICLE 3. Aurora Posts Q2 Earnings, Touts 562% Spike in ‘International Medical’ Cannabis Sales Total Cannabis Net Revenue Hovered $70.3 Million, Excluding Provisions of $2.7 Million, up 11% Over the Second Quarter of 2020 Aurora Cannabis (NYSE: ACB) released its second-quarter fiscal 2021 Earnings report Thursday afternoon. Here’s what we learned: Medical Cannabis net revenue reached $38.9 million — up 42% versus the second quarter of 2020. That jump was due to a 562% increase in high margin international medical sales. Aurora experienced an adjusted EBITDA loss of $12.1 million. That’s an improvement of $53.1 million over the second quarter of 2020. READ FULL AURORA CANNABIS ARTICLE 2. MindMed Signs Partnership With Swiss Psychedelic Drug Discovery Startup MindShift Compounds AG, Expands Development Pipeline and IP Portfolio with Next-Gen Psychedelic and Empathogenic Compounds As Part of This Partnership, MindMed and MindShift Compounds AG Have Agreed to Develop Next-Gen Psychedelic and Empathogenic Substances Together MindMed (OTCQB: MMEDF) (FRA: MMQ) announced a new partnership with Swiss startup MindShift Compounds AG to develop and patent next-gen Psychedelic compounds with psychedelic or empathogenic properties. The first initial compounds have already been synthesized by MindShift Compounds AG and related patent applications were filed by MindMed. MindMed plans to begin first-in-human Phase 1 clinical trials as early as Q1 2022 through its existing clinical trial platform for psychedelic and empathogenic compounds in Switzerland. READ FULL MINDMED ARTICLE 1. Why Cannabis MSOs Will ‘Outperform S&P 500’ in 2021 Top Cannabis Analyst Pablo Zuanic’s New Estimates Reflect Cantor Fitzgerald’s State-by-State Market Size Assumptions Most U.S. Multi-State Operators (MSOs) will outperform the S&P500 in the year ahead, according to Cantor Fitzgerald analyst Pablo Zuanic. A few standouts in Zuanic’s Thursday note on the space include Ayr Strategies (OTCQX: AYRSF), Green Thumb ((OTCQX: GTBIF) and Jushi Holdings (OTCQB: JUSHF). READ FULL CANNABIS MSOS ARTICLE 'Photo by Matthew Brodeur on Unsplash See more from BenzingaClick here for options trades from BenzingaCannabis Countdown: Top 10 Marijuana And Psychedelics Industry News Stories Of The WeekCannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Pornhub Payment Option Verge Suffers Massive Blockchain Reorganization

    Verge has been hit by a massive 560,000-block reorganization.

  • What Is Berkshire Hathaway’s Mystery Stock? Big Investment by Warren Buffett Could Be Disclosed Tomorrow.

    A large investment by Warren Buffett’s conglomerate, previously confidential, could be disclosed in a 13F filing tomorrow.

  • Natural Gas Skyrockets Again to $500 as Blackouts Spread in U.S.

    (Bloomberg) -- Natural gas for physical delivery in the U.S. was trading for as much as $500 per million British thermal units on Monday as demand for the heating and power plant fuel soared amid a deep freeze.Gas at two hubs in the U.S. Midcontinent was trading at $500 per mmBtu and went for $240 at a third on Monday, according to traders. Spot gas has been trading for hundreds of dollars across the central U.S. since Thursday with a surge in heating demand triggering widespread blackouts and sending electricity prices soaring. The fuel normally trades in the region for less than $3 per mmBtu. “It’s a shocking situation,” said Cody Moore, head of gas and power trading at Mercuria Energy America LLC. “It’s chaos. It’s crazy with the prices.” Mercuria booked hotel rooms for some of its employees in the Houston area so they could walk to the office instead of driving on icy roads. “Our first priority was to do whatever we can to keep the grid moving, the gas flowing properly, clients informed and regulatory agencies updated where required,” Moore said.Among other news in U.S. gas markets Monday:Front-month natural gas futures jumped 3.3% to $3.01 per mmBtuGas pipeline operator Oneok Inc. said its lines were “largely operational” but that the gas drillers it serves had seen their production decline due to the severe coldMore than 30 gas pipelines have declared force majeure or have instituted operational flow orders, which restrict the amount of fuel shippers can put on their systems, according to East Daley Capital.Gas production has fallen by more than 10 billion cubic feet a day over the past week, data compiled by BloombergNEF show.Read More: California Power Supplies Threatened by Deep Freeze in TexasFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • China targets rare earth export curbs to hobble US defence industry

    China is exploring limiting the export of rare earth minerals that are crucial for the manufacture of American F-35 fighter jets and other sophisticated weaponry, according to people involved in a government consultation. The Ministry of Industry and Information Technology last month proposed draft controls on the production and export of 17 rare earth minerals in China, which controls about 80 per cent of global supply. Industry executives said government officials had asked them how badly companies in the US and Europe, including defence contractors, would be affected if China restricted rare earth exports during a bilateral dispute.

  • If your $1,200 stimulus check had gone into these 8 stocks, you'd have cashed in big

    The prices of these big-name stock have multiplied since April 2020

  • In The EV Revolution The Battery Will Be The Key Competitive Differentiator

    The market for electric transportation is broad and varied, though many investors don’t give much thought to opportunities beyond industry behemoths like Tesla Inc (NASDAQ: TSLA). In recent months, however, a growing number of investors and observers have seen past the recognizable names and are justifiably excited about the emerging opportunities they see in e-transportation and e-mobility. For example, shares of BYD Co Ltd (OTC: BYDDY), for which I was the first investor in 1995, have gained a hefty 300% in the past six months on heightened awareness. If you’re familiar with BYD – whose largest equity holder is now Berkshire Hathaway (NYSE: BRK-B) - you know the company as a maker of electric buses or industrial equipment such as forklifts and trucks. What you may not know is that BYD began as a battery company, and that despite being the world’s largest maker of electric vehicles in 2016, it still primarily views itself as a battery maker. In fact, just two years ago, BYD was in the process of building the largest battery factory in the world. That breakneck growth has continued and shows little signs of slowing down. In fact, last month BYD Co Ltd raised $3.86 billion from an upsized sale of its Hong Kong-listed shares, capitalizing on growing demand for its new-energy vehicles. Automakers that view their core operation as a battery company are common; people in the e-mobility market know they are in the battery business first and the car or shipping business second. In 2015, Elon Musk said exactly the same thing. Five years later, Social Capital CEO Chamath Palihapitiya echoed the same sentiment when he told CNBC Tesla’s growth is much more than about electric cars: its renewable energy components could be worth trillions. Still, while many investors see spin-off opportunities in electric vehicles (EV), they likely miss that EVs themselves are spin-offs of battery technologies. In this market, just as with the cars and buses themselves, the batteries (no pun intended) are the drivers. Take robotics as another example. Privately held UBTech, the world’s most valuable consumer robotics company (valued at about $10 billion), for which I am an investor and serve as board member, is also driven by advancements in battery technology. In robotics, a battery’s weight, energy density and ability to safely charge and discharge is everything. That’s another reason why investors looking long term would be wise to source opportunities in batteries and battery-related technologies. By betting on batteries, you’re not only betting on Tesla, or Volkswagen, but also on robotics and satellite tech, shipping and grid-level energy storage, and mass transit. Even consumer electronics such as laptops, mobile phones and AR/VR headsets run on - you guessed it - batteries. That’s why my investment firm backs companies that pioneer safer, more efficient, and lighter weight batteries. An example being California-based KULR Technology Group (OTC: KULR). KULR takes space proven technology to make lithium battery systems cooler, lighter and safer for consumers. You can see why, in the battery world, that’s a big deal. They have been working on this technology for many years with NASA. Now they are deploying it to EV, energy storage and many other commercial applications. The market opportunity is huge for what they do. Generally speaking, backing battery companies may feel like placing a wager on a very specific technology. But it’s really like investing in multiple, high-growth, high-return markets at once. If a single advancement in battery technology works, it doesn’t just work for a confined vertical - it works everywhere. So, if you’re following car makers or e-mobility, or feel as though you may have missed early investment opportunities there, it may be a good time to see them differently -- to see them as battery companies. That’s what most of them really are. Xia Zuoquan is a founding investor and director of BYD Co Ltd, a maker of electric buses and plug-in electric cars and batteries. Xia founded investment firm Zhengxuan Capital in 2004, with an estimated $1.5 billion in assets. See more from BenzingaClick here for options trades from BenzingaMr. Musk: Will You Just Trade For Me?New Tesla Roadster Patent Shows Wild Windshield Wiper Design© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • What Keystone Pipeline Cancellation Means For Crude-by-rail

    President Joe Biden's revocation of the March 2019 permit enabling the construction of the Keystone XL pipeline will likely result in more crude-by-rail volumes, according to industry observers. But how much volumes will increase could largely depend on the price that heavy crude oil can fetch in the global market. "The cancellation of the Keystone pipeline project was inevitable once the government changed. Despite its merits or drawbacks, it is now a deflated political football," said Barry Prentice, University of Manitoba supply chain management professor and former director of the Transport Institute there. "This means that more crude will have to move by rail. The huge investments in the oil sands will not be abandoned, and the oil has to go somewhere." But crude-by-rail "has been problematic because with the low price for oil, and the relatively higher price for rail transport, nothing looks very appealing. The problem is not oil supply, it is the reduced demand during the pandemic. Once we come out of this period, demand will return, and $100-per-barrel oil will, too," Prentice said. Indeed, the oil markets serve as one highly visible factor determining how much crude gets produced and shipped. For the production and transport of heavy crude oil from western Canada and the U.S. to be profitable, the pricing spread between a heavy crude product such as Western Canadian Select (WCS) and a light, sweet crude such as West Texas Intermediate (WTI) needs to be favorable. WCS crude is typically priced at a discount against WTI crude because of its lower quality and its greater distance from the U.S Gulf Coast refineries. The COVID-19 pandemic was among the factors that contributed to WTI crude oil prices' tailspin in 2020. Why the interest in crude oil production and transport? The oil market isn't the only factor that dictates crude oil production and its subsequent transport. Another is the vast oil reserves and the amount of investment already directed into crude oil production, as well as crude oil's export prospects. According to the government of Alberta, the province's oil sands represent the third-largest oil reserves in the world, following Venezuela and Saudi Arabia. Its reserves equal about 165.4 billion barrels, and capital investments to the upstream sector have equaled as much as $28.3 billion in 2016 and $26.5 billion in 2017. Furthermore, according to Natural Resources Canada, 98% of Canada's crude oil exports in 2019 went to the U.S. Those investments and vast oil reserves have also resulted in significant investments in other areas of the energy sector, including investments in pipelines. The pipelines bring Canadian heavy crude south to U.S. refineries because American refineries were built and optimized to mostly handle heavier crude oil, according to Rob Benedict, senior director of petrochemicals, transportation and infrastructure for the American Fuel and Petrochemical Manufacturers Association. Crude oil pipelines from Canada to the U.S. have been viewed as an efficient way to transport large amounts of Canadian heavy crude oil to U.S. Gulf Coast refineries. TC Energy's 1,210-mile Keystone XL pipeline would have had a capacity of 830,000 barrels per day with crude oil originating from Hardisty, Alberta, and heading to Steele City, Nebraska, where it would then be shipped to U.S. Gulf Coast refineries. Had construction continued, the pipeline would have entered service in 2023. But TC Energy abandoned the project after Biden revoked an existing presidential permit for the pipeline in January. "TC Energy will review the decision, assess its implications, and consider its options. However, as a result of the expected revocation of the Presidential Permit, advancement of the project will be suspended.The company will cease capitalizing costs, including interest during construction, effective January 20, 2021, being the date of the decision, and will evaluate the carrying value of its investment in the pipeline, net of project recoveries," TC Energy said in a release last month. The Keystone XL pipeline "is an essential piece that would have allowed Canada and the U.S. to continue the very good relationship they have with transporting energy products across the border," Benedict said. However, suspending pipeline construction doesn't necessarily translate into a one-for-one increase in crude-by-rail volumes, according to Benedict. "The gist of the story is, it's going to have some impact on crude-by-rail. It's not going to shift all 830,000 barrels per day onto the rails, but any additional amount is potentially going to have some impact," Benedict said. Several factors will influence how much crude moves by rail. In addition to the WCS/WTI price spread, the railways' capacity to handle crude-by-rail is crucial. Not only are there speed restrictions for crude trains and possible social ramifications, there also capacity issues. The Canadian railways have reported record grain volumes over the past several months, and crude volumes must compete with grain, as well as other commodities, for the same rail track. There are also other pipelines between Canada and the U.S. that could take some of the volumes that would have been handled by the Keystone XL pipeline, Benedict said. Those include Endbridge's (NYSE: ENB) Line 3 pipeline, which runs from Canada to Wisconsin; Endbridge's Line 5 pipeline, which runs under the Strait of Mackinac and Lake Michigan to the Michigan Peninsula; and the Trans Mountain pipeline that's under development in Canada. It would run from Alberta to the Canadian West Coast and then potentially south to U.S. refineries. And one other factor that could influence crude-by-rail is how much crude oil volumes go into storage, Benedict said. "It's not just a simple question of, does one pipeline being shut down ship all to rail? It's complex because you have to consider all the different nodes of the supply chain, including storage that would come into play," Benedict said. The Canadian railways' views on crude-by-rail For their part, Canadian Pacific (NYSE: CP) and CN (NYSE: CNI) have both said they expect to ship more crude volumes, but neither has indicated just how much volumes will grow. CP said during its fourth-quarter earnings call on Jan. 27 that it has been seeing increased activity as price spreads have become favorable. The railway also expects to begin moving crude volumes from a diluent recovery unit (DRU) near Hardisty, Alberta. US Development Group and Gibson Energy had agreed to construct and operate the DRU in December 2019. As part of that agreement, ConocoPhillips Canada will process the inlet bitumen blend from the DRU and ship it via CP and Kansas City Southern (NYSE: KSU) to the U.S. Gulf Coast. "These DRU volumes will provide a safer pipeline-competitive option for shippers and will help to stabilize our crude business into the future," CP Chief Marketing Officer John Brooks said during the earnings call. CP President and CEO Keith Creel also said he sees U.S. actions on the Keystone pipeline as benefiting crude-by-rail and the DRU volumes. The actions "bode for more strength and more potential demand for crude. We think it creates more support for scaling up and expansion of the DRU. So, we're bullish on that opportunity," Creel said. He continued, "We still see the short-term, not long-term ... pipeline capacity [eventually] catch up [but] we just think there is a longer tail on it right now. So, we think there's going to be a space for some potential upside in both spaces." Meanwhile, in a Jan. 27 interview with Bloomberg, CN President and CEO JJ Ruest called crude-by-rail a "question mark" in terms of what energy outlook the railway is seeing for 2021. Ruest said low oil prices, decreased travel and the Keystone pipeline cancellation are among the factors influencing CN's energy outlook. However, crude-by-rail could be a "slight positive bump on the rail industry," Bloomberg quoted Ruest as saying. CP and CN declined to comment further to FreightWaves about crude-by-rail, and CN directed FreightWaves to the Bloomberg article. Subscribe to FreightWaves' e-newsletters and get the latest insights on freight right in your inbox. Click here for more FreightWaves articles by Joanna Marsh. Related articles: Social risk trumps financial risk for Canadian crude-by-rail Transport Canada issues new speed restrictions for trains hauling dangerous goods Construction of Alberta crude unit expected to start in April Commentary: Railroad tank cars take a hit See more from BenzingaClick here for options trades from BenzingaForward Air Doubles Down Amid Heightened Interest From ActivistsDrilling Deep: Reviewing Q4 Earnings; How Did Werner Do So Well?© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Stocks Set for Longest Winning Streak Since 2003: Markets Wrap

    (Bloomberg) -- Global stocks are in the midst of the longest run of gains since 2003 as optimism over the economic recovery sweeps across markets.The MSCI World Index has risen for 12 straight sessions and U.S. equities were poised to open higher after the Presidents Day holiday. In Japan, the Nikkei 225 Stock Average extended its advance past the 30,000 level. European markets steadied after a rally on Monday.The reflation trade is powering assets tied to economic growth and price pressure, including commodities and cyclical stocks. At the same time, investors are riding a wave of speculative euphoria from penny stocks to Bitcoin amid abundant policy support.“Continued monetary stimulus and bursts of fiscal support maintain a strong foundation for risk assets,” said Seema Shah, chief strategist at Principal Global Investors.Here’s a look at how it’s playing out in global markets:CommoditiesBrent oil is holding near a 13-month high after freezing temperatures crippled the Texas power system and disrupted crude production. Nearly 5 million people across the U.S were plunged into darkness as homes and businesses lost power. Natural gas futures for March delivery surged as much as 6.3%.In metals, copper climbed to the highest since 2012 and tin extended a dramatic surge. Citigroup Inc. forecasts copper prices will rally to $10,000 a ton in six to 12 months on a better-than-expected recovery in demand, most notably outside China.U.S. Energy Crisis Deepens With Nearly 5 Million in the Dark BondsGlobal debt markets are extending a selloff as investors shift money to riskier assets. German bunds and U.K. gilts both saw benchmark yields gain five basis points. Treasury 10-year yields rose four basis points to touch 1.25% -- the highest since last March -- while the 30-year equivalent pushed above 2%.CurrenciesThe dollar slipped against most of its major peers as haven bids waned. The pound gained for a third day, closing in on $1.40, amid signs that trade between the U.K. and European Union is normalizing.Bitcoin reached another record, coming ever closer to $50,000. A flurry of recent announcements indicates the cryptocurrency is winning more mainstream attention, after Tesla Inc.’s purchase catapulted it onto the agenda of corporate treasurers.Here are some key events coming up:Earnings roll on with companies including, Daimler, Credit Suisse, Deere, Danone and Nestle.Euro-area finance ministers will discuss the bloc’s current economic situation and outlook on Tuesday.Federal Open Market Committee minutes from the January meeting are due Wednesday.U.S. retail sales figures come on Wednesday.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • New Bill Could Net More Tesla, Ford And GM EV Buyers A $7,000 Tax Credit

    What Happened: $7,000 of tax credit may soon be given to hundreds of thousands more U.S. electric vehicle buyers with a potential overhaul of purchasing incentives coming to the states. The Growing Renewable Energy and Efficiency Now (GREEN) Act, legislation introduced by democrats, looks to increase tax credits issued to EV buyers. In all likelihood, American EV makers Tesla Inc (NASDAQ: TSLA), Ford Motor Company (NYSE: F) and General Motors Company (NYSE: GM) would stand to gain the most given Tesla's current global sales are, while Ford and GM continue their push into the market. Here are the details of the legislation involving the EV industry at large: The provision expands the qualified plug-in electric drive motor vehicle credit under Section 30D to apply a new transition period for vehicle sales of a manufacturer between 200,000 and 600,000 electric vehicles (EVs), under which the credit is reduced by $500. The provision replaces the current phaseout period (which begins at 200,000 vehicles) with a phaseout period that instead begins during the second calendar quarter after the 600,000-vehicle threshold is reached. At the start of the new phaseout period, the credit is reduced by 50% for one quarter and terminates thereafter. For manufacturers that pass the 200,000-vehicle threshold before the enactment of this bill, the number of vehicles sold in between 200,000 and those sold on the date of enactment are excluded to determine when the 600,000-vehicle threshold is reached. Why It Matters: Democrats are back in the White House with the House and Senate majorities in hand. It's expected the Biden administration’s embrace of clean energy will provide favorable business conditions for EV makers in the coming years, providing strength to the electric vehicle, fuel cell and biogas industries at large. See Also: How To Buy Tesla Stock, How To Buy Ford Stock And How To Buy GM Stock See more from BenzingaClick here for options trades from BenzingaGE Declares Regular Quarterly DividendMark Zuckerberg Told Facebook Staff In 2018 To 'Inflict Pain' On Apple: Report© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • 12 tax red flags that could lead the IRS to audit you

    IRS audit flags can stem from things you do — or don't do — when filing your tax return.

  • Semiconductor cycle out of balance after customers stock up

    In an industry as cyclical as semiconductors, there is always either too much or too little supply. For the companies that design and use microchips, the past 30 years have been a constant exercise in securing the right amount of them to satisfy demand but not tying up too much money in inventory.

  • Taiwan’s economy feels heat as TSMC feeds global chip boom

    Business has never been brisker for construction companies in Taiwan as the world’s biggest contract chipmaker rushes to build facilities through the Lunar New Year holiday to meet surging demand. TSMC, which produces chips for tech companies such as Apple, Google and Qualcomm, told builders it would pay lucrative premiums to ask many of their workers — after only two days off — to begin work a little earlier during the period surrounding the island’s most important annual lunar new year holiday, which started this year on February 10, people with knowledge of the matter told Nikkei Asia. TSMC is also constructing a research and data centre in the northern city of Hsinchu.